Agios Pharmaceuticals said Monday that its drug called mitapivat reduced the need for blood transfusions in patients with a severe form of beta-thalassemia, an inherited blood disorder. The results achieved the primary goal of a placebo-controlled Phase 3 clinical trial, and if the drug is eventually cleared by regulators, could accelerate sales.
In the study, 30% of participants responded to treatment with mitapivat compared to 12% of participants offered a placebo. Response was defined as a 50% reduction in the transfusion of red blood cell units in any 12-week period during the 48-week course of the study.
The placebo-adjusted reduction in transfusion burden shown by mitapivat is lower than what’s been seen with Reblozyl, a competing drug for transfusion-dependent beta-thalassemia marketed by Bristol Myers Squibb. The two drugs have not been compared directly against each other and Bristol’s study used a different definition of transfusion response.
Click this link for the original source of this article.
Author: Adam Feuerstein
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.